Neuberger Berman Group LLC Sells 3,315 Shares of Amgen Inc. $AMGN

Key Points

• Neuberger Berman trimmed its Amgen stake by 2.2%, selling 3,315 shares and leaving 144,031 shares valued at about $40.65 million at the end of the quarter; institutional investors own roughly 76.5% of the stock.
• Amgen beat quarterly revenue ($9.87B) and EPS ($5.29 vs. $4.76 est.), provided FY‑2026 EPS guidance of 21.600–23.000, and declared a $2.52 quarterly dividend (annualized $10.08, ~2.7% yield).
• Rocatinlimab trials halted: Amgen and partner Kyowa Kirin stopped all rocatinlimab studies after safety signals linking OX40 pathway modulation to malignancies, marking a notable pipeline setback.

Neuberger Berman Group LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 144,031 shares of the medical research company's stock after selling 3,315 shares during the period. Neuberger Berman Group LLC's holdings in Amgen were worth $40,646,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Intellectus Partners LLC increased its position in shares of Amgen by 226.3% during the 3rd quarter. Intellectus Partners LLC now owns 3,224 shares of the medical research company's stock worth $910,000 after purchasing an additional 2,236 shares during the last quarter. Foster Dykema Cabot & Partners LLC boosted its holdings in shares of Amgen by 82.6% in the 3rd quarter. Foster Dykema Cabot & Partners LLC now owns 767 shares of the medical research company's stock valued at $216,000 after buying an additional 347 shares during the last quarter. Guardian Capital LP boosted its holdings in shares of Amgen by 7.4% in the 3rd quarter. Guardian Capital LP now owns 25,366 shares of the medical research company's stock valued at $7,158,000 after buying an additional 1,753 shares during the last quarter. LOM Asset Management Ltd grew its stake in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after buying an additional 30 shares in the last quarter. Finally, Integrity Advisory Solutions LLC bought a new position in shares of Amgen in the third quarter valued at $1,017,000. Institutional investors own 76.50% of the company's stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Trading Up 0.5%

AMGN stock opened at $369.53 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a fifty day moving average price of $353.26 and a two-hundred day moving average price of $322.43. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The stock has a market cap of $199.20 billion, a price-to-earnings ratio of 25.97, a price-to-earnings-growth ratio of 3.65 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio is currently 70.84%.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. UBS Group upped their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. DZ Bank lifted their price objective on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Argus boosted their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Citigroup upped their target price on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Finally, Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They issued an "equal weight" rating and a $350.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of "Hold" and a consensus price target of $354.17.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.